All news from Immuno Haematology & Blood Transfusion

Non-alcoholic Fatty Acid Liver Could Be Improved By Gastrointestinal Hormone

Through a randomized, double-blind, placebo-controlled phase II clinical trial, at the University of California San Diego School of Medicine report that small doses of NGM282, a non-tumorigenic variant of an endocrine gastrointestinal hormone, can significantly and rapidly decrease liver fat content in patients with non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).